Quintiles has scooped up a provider of genomic testing and analysis as the global pharma services company beefs up its internal capabilities to support the development of personalized drugs. With the buyout of Expression Analysis, Quintiles builds on a series of acquisitions and alliances that advance the genomics revolution into research labs and clinical trials, where drugs are being designed and developed to home in on the specific molecular drivers of disease found in discrete groups of patients. It will keep the existing Expression Analysis operation in Research Triangle Park, NC, where it has most of its 77 employees, and fold it into its own organization. From its labs near Quintiles' own North Carolina headquarters, Expression Analysis offers whole-genome and focused-set gene expression and genotyping assays as well as next-generation sequencing, sequence enrichment and bioinformatics services. And its capabilities enable researchers and drug developers to, say, identify patients likely to respond to a drug in clinical trials based on their genetic makeup. The deal was announced Monday morning. Article
Like what you're reading?
Click here to get more news delivered to your inbox every week>>